Funded Biotechnology Startups
The 27 rounds shown span late September through late November 2025, covering companies headquartered across the United States, China, Germany, Italy, Japan…
The 27 rounds shown span late September through late November 2025, covering companies headquartered across the United States, China, Germany, Italy, Japan, and South Korea. US-based firms make up roughly 15 entries — Boston appears twice (Modulight Bio, Predicta Biosciences), with additional deals in San Francisco, New York, Philadelphia, and a spread of smaller US cities. China contributes six companies, including two Shanghai-based rounds: GRIT Biotechnology's $84M Series C and Huadao Biopharma's undisclosed Series D, both closed in October 2025.
The three largest disclosed rounds — Expedition Therapeutics ($165M Series A, San Francisco), AAVantgarde Bio ($141M Series B, Milan), and NILO Therapeutics ($101M Series A, New York) — all closed in October 2025. Seed rounds are the most frequent stage at nine of 27, ranging from AccufyDx's $200K in Rockville to Modulight Bio's $12M in Boston. Nine rounds list undisclosed amounts, spanning Series B through private equity stages.
Most recent rounds
27 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this segment?
The top five by disclosed amount are Expedition Therapeutics ($165M Series A, San Francisco, October 2025), AAVantgarde Bio ($141M Series B, Milan, November 2025), NILO Therapeutics ($101M Series A, New York, October 2025), GRIT Biotechnology ($84M Series C, Shanghai, October 2025), and Reprogenix ($70M Series A, Hangzhou, November 2025).
Where are most of these biotech and healthcare companies based?
US companies account for roughly 15 of the 27 entries, distributed across cities including Boston, San Francisco, New York, Philadelphia, and Rochester. China contributes six companies spanning Beijing, Hangzhou, Shenzhen, Shanghai, and Chengdu. Germany, Japan, Italy, and South Korea each have one or two entries.
Which funding stage appears most frequently in this data?
Seed is the most frequent stage with nine rounds, followed by Series A with eight. The seed cohort spans a wide range — from AccufyDx's $200K in Rockville to Modulight Bio's $12M in Boston.
How many of these rounds have undisclosed funding amounts?
Nine of the 27 rounds list undisclosed amounts, including LASO Biotech's Series B (Beijing), Huadao Biopharma's Series D (Shanghai), Repairon's Series A (Göttingen), and Real Diagnostics' private equity round (Reisterstown). Undisclosed deals appear across every stage from Venture - Series Unknown through Series D.
Are there any Series C or later-stage rounds in this dataset?
Two rounds are Series C or beyond: GRIT Biotechnology's $84M Series C (Shanghai, October 2025) and Huadao Biopharma's undisclosed Series D (Shanghai, October 2025). Real Diagnostics (Reisterstown) also completed a private equity round, though the amount is undisclosed.
Which cities appear more than once in this dataset?
Boston has two entries — Modulight Bio (Seed, $12M) and Predicta Biosciences (Series A, $23M). Shanghai also appears twice with GRIT Biotechnology (Series C, $84M) and Huadao Biopharma (Series D, undisclosed).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.